Can I Buy Incyte Corporation Shares in India?

Yes, Incyte Corporation shares can be bought in India by opening an international trading account with Groww.

How to Buy Incyte Corporation Shares in India?

One can easily invest in Incyte Corporation shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Incyte Corporation shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Incyte Corporation.

What is the Share Price of Incyte Corporation?

The share price of Incyte Corporation is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Incyte Corporation share price is $71.94 as of 14 Jan ‘25

What is the Market Cap of Incyte Corporation?

The Incyte Corporation market cap is $13.85B as of 14 Jan ‘25

What is the PE and PB ratio of Incyte Corporation?

The PE and PB ratio of Incyte Corporation is 426.6 and 4.4 as of 14 Jan ‘25

Incyte Corporation Share Price, INCY Stock Price Quote Today

<img alt="Incyte Corporation" srcSet="https://viewlogo.s3.amazonaws.com/66740/conversions/258427-default.png 1x, https://viewlogo.s3.amazonaws.com/66740/conversions/258427-default.png 2x" src="https://viewlogo.s3.amazonaws.com/66740/conversions/258427-default.png" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="companyLogo_companyImage__bT0On absolute-center uspp14Logo" loading="lazy"/>
Incyte Corporation Healthcare 
$71.94
-0.43(0.59%) 1D
1D
1W
1M
1Y
3Y
5Y
Performance
Open PricePrev. CloseVolumeAvg. Volume
$72.34$72.371,595,9171,750,681
FundamentalsMarket Cap$13.85B
P/B Ratio4.4
P/E Ratio426.6
Enterprise Value$12.58B
Div. Yield0.00%
Book Value22.01
EPS(TTM)0.76
ROENA
Understand Fundamentals
FUNDAMENTALS
It is financial information that is reported quarterly or annually.
Market Cap
Market cap or market capitalization is the total market value of all of a company's outstanding shares.
Div. Yield
The divided yield displayed as a percentage is the amount of money a company pays shareholders for owning a share of its stock divided by its current stock price
P/B Ratio
The price-to-book ratio is a company's current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock.
Book Value
The book value of a stock is theoretically the amount of money that would be paid to shareholders if the company was liquidated and paid off all of its liabilities.
P/E Ratio
The price-earnings ratio is a company's share price to the company's Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued.
EPS(TTM)
Earnings per share (EPS) is a company's net profit divided by the number of common shares it has outstanding. EPS indicates how much money a company makes for each share of its stock, and is widely used metric to estimate corporate value
Enterprise Value
Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
ROE
Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholder's equity
About the CompanyIncyte Corp is a Wilmington, Delaware based biopharmaceutical company with an extensive global presence. With approximately 1,500 employees, the company has operations in the United States, Japan and Europe. With expertise in medicinal chemistry and biology, Incyte develops products, helmed by world-class scientists. 
The company produces medicines under two franchises - Inflammation & Autoimmunity and Oncology. However, it develops medicines for four therapeutic areas, namely Immunology, Oncology, Rheumatology and Dermatology. As of 2020, it has 19 molecular targets and 22 clinical candidates it is working upon. Some of its medicines are Jakafi, INCB00928, INCB86550, Pemigatinib, Iclusig, Pemazyre, Monjuvi, Tabrecta, Olumiant, etc. The molecules it is developing for its drugs include FGFR, JAK, ARG, GITR, LAG-3, PI3Kδ, PD-1/PD-L1, TIM-3, etc. 
Between 2009 and 2020, Incyte has collaborated with ten companies, producing medicines like capmatinib20, Tabrecta, baricitinib17 and Olumiant. Few of the notable companies it has partnered with are Eli Lilly and Company, Agenus Inc., MacroGenics Inc., MorphoSys AG, Novartis International Pharmaceutical Ltd., Zai Lab, Ltd., Merus N.V., Innovent Biologics, Inc., ARIAD Pharmaceuticals, Inc. and Calithera Biosciences, Inc.
Incyte was formed in 2002 by a group of scientists, biologists and chemists who were working in immunology. As of 2020, it is an S&P 500 component as well as a NASDAQ 100 component. It trades in the NASDAQ stock exchange under the ticker symbol INCY. It holds the 953rd rank in the 2020 Fortune 1000 list of companies. In the same year, it made into the Forbes list of Global 2000 companies. In 2018, it was the 7th most innovative company in the world, according to Forbes rankings.;
OrganisationIncyte Corporation
IndustryBiotechnology
HeadQuartersWilmington, DE
Company Financials
*All values are in Million $
No Graph Data To Display
Quarterly
Yearly
See Details
Similar StocksCOMPANYMARKET PRICECLOSE PRICEMARKET CAP

Vaishnavi Tech Park, 3rd & 4th Floor
Sarjapur Main Road, Bellandur
Bengaluru – 560103
Contact Us
PRODUCTS
StocksFutures & OptionsMTFIPOMutual FundsNFOETFCreditBill Payments
GROWW
About UsPricingBlogMedia & PressCareersHelp and SupportTrust and Safety
QUICK LINKS
AMC Mutual FundsCalculatorsGlossaryOpen Demat AccountGroww DigestSitemapWeb Stories
ⓒ 2016-2025 Groww. All rights reserved, Built with ♥in India

Open Price	Prev. Close	Volume	Avg. Volume
$72.34	$72.37	1,595,917	1,750,681

Market Cap	$13.85B
P/B Ratio	4.4
P/E Ratio	426.6
Enterprise Value	$12.58B

Organisation	Incyte Corporation
Industry	Biotechnology
HeadQuarters	Wilmington, DE